SPC454
Dengue fjórgilt bóluefni (lifandi, deyft): Dengue-veira sermigerð 1 (lifandi, deyfð), þar sem genum með sermigerðar-sértækum yfirborðsprótínum er breytt í dengue gerð 2 hrygg Dengue-veira sermigerð 2 (lifandi, deyfð), Dengue-veira sermigerð 3 (lifandi, deyfð), þar sem genum með sermigerðar-sértækum yfirborðsprótínum er breytt í dengue gerð 2 hrygg Dengue-veira sermigerð 4 (lifandi, deyfð), þar sem gen með sermigerðar-sértækum yfirborðsprótínum er breytt í dengue gerð 2 hrygg.
Status:
UmsóknApplication date:
15.2.2024Application published:
15.3.2024
Max expiry date:
5.12.2037Medicine name:
QdengaMedicine for children:
No
Timeline
Today
15.2.2024Application
15.3.2024Publication
5.12.2037Expires
Marketing license
IS authorization number:
EU/1/22/1699Date:
15.12.2022
Foreign authorization number:
EU/1/22/1699Date:
6.12.2022
Owner
Name:
Takeda Vaccines, Inc.Address:
75 Sidney Street, Cambridge, MA 02139 US
Name:
The Government of The United States of America as represented by The Secretary of The Department of Health and Human ServicesAddress:
4770 Buford Highway Technology Transfer Office (K79), Atlanta, GA 30341 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP4129330
Deadlines
TypeDeadline until
Type: Formgallafrestur, fyrsti
Deadline until: 23.05.2024